evt_6f80ef86-497f-54bf-8eab-8adbb27f6910selinexor
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
phase3_result
evd_0415889c-fc0c-544e-9be6-7501f8c06b44, evd_197c5e3c-885d-501b-a1a5-025d36236f87, evd_220df2bc-e37d-50d3-8577-7962f62b483b, evd_25ad3d72-27e1-5d33-9be0-f377c1333e62, evd_3112ba2e-1c2b-5023-9398-349c8b6fb275, evd_3a357ef6-41a1-59fa-849a-5a5ddcf3ce5a, evd_4b9ee43f-8ac1-5025-86b9-785849b02996, evd_76fddde4-0623-5632-bf89-793cd5a5dc77, evd_8ce62b61-10f7-5dfa-b98a-ffe1ca314dc9, evd_af6b54e1-ad20-546c-8242-40ab4e13f5c8, evd_d6b80efa-c464-54f8-8698-0621dcc9e411fact_11ced85e-4b2d-554c-94d0-fe89a8eaf2b7, fact_2bc4ba8b-aa36-5da2-9c55-c35789b0bf88, fact_38d85417-21b4-5381-92e9-675d249edb54, fact_3b7b5326-2ff7-5f9c-adf1-35fd45c38a9c, fact_916dfcd8-a235-5128-9175-ebd9a65a1264, fact_ab19ce03-e226-5555-92b0-e503cbf9599erel_3098008c-048f-586e-a67b-d6843660a566, rel_4a725d23-778f-5ffe-9a55-c8bda9d9e6a1, rel_bf5cc59e-a46e-5c64-9b6f-b356907a6389, rel_d33badd0-10de-54e5-b187-55df673551eb